Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises ... biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. read more